Table 1.

Baseline characteristics of all patients with a first-in-study-period intracerebral haemorrhage ascertained in Oxford Vascular Study (2002–2018) stratified by haematoma location

	Total (n=255)*	Lobar ICH (n=109)	Non-lobar ICH (n=144)	P value
Age (mean/SD)	75.5/13.1	76.4/12.0	74.8/13.8	0.34
Male sex	126 (49.4)	50 (45.9)	76 (52.8)	0.28
NIHSS (median, IQR)†	8 (4–16)	9 (4–17)	8 (4–15)	0.94
Medical history
Previous TIA or ischaemic stroke	73 (28.9)	39 (35.8)	34 (23.6)	0.03
MI or peripheral vascular disease	21 (8.3)	15 (13.8)	6 (4.2)	0.006
Hypertension	156 (61.2)	58 (53.2)	97 (67.4)	0.02
Diabetes mellitus	36 (14.1)	14 (12.8)	22 (15.3)	0.58
Hyperlipidaemia	59 (23.1)	24 (22.0)	35 (24.3)	0.67
Atrial fibrillation	57 (22.4)	24 (22.0)	33 (22.9)	0.87
History of smoking‡	116 (47.0)	47 (45.2)	69 (48.9)	0.56
Current smoker§	24 (9.7)	10 (9.5)	14 (9.9)	0.92
Premorbid medication
Antithrombotics¶	122 (47.8)	55 (50.5)	66 (45.8)	0.47
Anticoagulants	54 (21.2)	27 (24.8)	27 (18.8)	0.25
Antiplatelet treatment	73 (28.6)	30 (27.5)	42 (29.2)	0.77
Antihypertensive treatment	126 (49.4)	48 (44.0)	77 (53.5)	0.14
Statins	66 (25.9)	36 (33.0)	29 (20.1)	0.02
Antithrombotics at discharge**	(n=143)	(n=60)	(n=83)
Anticoagulants	1 (0.7)	1 (1.7)	0 (0)	0.24
Antiplatelet treatment	7 (4.9)	5 (8.3)	2 (2.4)	0.11

Numbers are presented as n (%) unless otherwise stated.

*n=2 with unknown location due to out-of-area death and no imaging was not accessible.

†Data missing for n=6.

‡Data missing for n=8.

§Data missing for n=7.

¶n=5 patients on both anticoagulant and antiplatelet drugs (n=2 for lobar and n=3 for non-lobar).

**Excluding patients that died prior to discharge.

ICH, intracerebral haemorrhage; MI, myocardial infarction; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischaemic attack.